TransCode Therapeutics, Inc.

Stocks

RNAZ

US89357L5012

Delayed Nasdaq 02:49:25 2026-09-04 pm EDT			5-day change	1st Jan Change
2.060 ^USD	-4.41%		-5.50%	-69.84%

Aug. 31	TransCode Therapeutics, Inc Announces Publication Demonstrating Survival Benefit Of TTX-MC138 In Preclinical Model Of Breast Cancer Bone Metastasis	CI
Aug. 14	TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Transcript : TransCode Therapeutics, Inc. - Special Call

Published on 06/18/2026 at 12:20 pm EDT - Modified on 06/18/2026 at 01:20 pm EDT

S&P Capital IQ

Presenter Speech
Philippe Calais (Executives)

Good morning, everyone, and thank you very much for joining us for this first ever webcast to cover our company research and corporate strategy. I'm

This article is reserved for our subscribers.

To unlock the article,
subscribe!

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about TransCode Therapeutics, Inc.

Aug. 31	TransCode Therapeutics, Inc Announces Publication Demonstrating Survival Benefit Of TTX-MC138 In Preclinical Model Of Breast Cancer Bone Metastasis	CI
Aug. 14	TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jun. 18	TransCode Therapeutics, Inc. - Special Call
Jun. 03	TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a	MT
Jun. 03	Transcode Therapeutics Completes Phase 1A Clinical Trial and Advances Ttx-Mc138 to Phase 2A Development	CI
May. 27	TransCode Therapeutics Initiates Phase 2a Clinical Trial With TTX-MC138 In Patients With ctDNA Positive Colorectal Cancer	CI
May. 15	TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 01	TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal	MT
Apr. 27	Transcode Therapeutics appoints Dr. Anna Moore as chair of scientific advisory board	RE
Apr. 27	TransCode Therapeutics, Inc. Appoints Anna Moore as Chair of Scientific Advisory Board	CI
Apr. 15	TransCode Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 14	TransCode Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
Apr. 05	TransCode Therapeutics, Inc. announced that it expects to receive $19.7 million in funding from Yorkville Advisors Global LP	CI
Mar. 03	Transcode Therapeutics, Inc. and Unleash Immuno Oncolytics, Inc. Secure Exclusive, Worldwide, Fully Paid-Up Royalty-Free License Agreement	CI
Mar. 03	TransCode Therapeutics Inc - enters exclusive license agreement with Unleash	RE

Chart TransCode Therapeutics, Inc.

Duration

Period

RNAZ: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

More financial data